A study evaluating the economic burden associated with multiple myeloma and its treatment has found that routine management and disease progression continues to drive healthcare resource utilization, regardless of the number of previous lines of therapy. Other key drivers of healthcare utilization in multiple myeloma are hospitalizations, transplantations, and concomitant medication use. The study was presented at ASCO 2016.
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology - In the Literature, Prostate Cancer
- Ixazomib Extends Progression-Free Survival in Multiple Myeloma
- Pembrolizumab Shows Potential Antitumor Activity in Advanced Gastric Cancer
- ASCO Endorses Canadian Clinical Practice Guideline on Active Surveillance for Localized Prostate Cancer
- Delayed Relapses After Anti–PD-1 Therapy Linked to Mutation in Patients with Melanoma
Adding the BCL-2 Inhibitor Venetoclax to Treatment Regimen Promising in Relapsed or Refractory Multiple Myeloma
The addition of venetoclax, an oral selective small-molecule BCL-2 inhibitor, to bortezomib and dexamethasone resulted in impressive response rates in a phase 1b trial of patients with heavily pretreated relapsed or refractory multiple myeloma, said Cyrille Touzeau, MD, of Centre Hospitalier Universitaire de Nantes, France, who presented the trial’s results at ASCO 2016.
When added to standard chemotherapy, IMAB362, a chimeric monoclonal antibody against the claudin 18.2 protein, reduced the risks for disease progression and death by 50% compared with standard chemotherapy alone as first-line treatment for patients with advanced or recurrent gastric cancer and gastroesophageal junction carcinomas, according to data presented at ASCO 2016.
Short-course (hypofractionated) radiotherapy plus concomitant and adjuvant temozolomide therapy significantly prolonged survival versus short-course radiotherapy alone in elderly patients with newly diagnosed glioblastoma. These results of a global cooperative group phase 3 clinical trial were 1 of 4 presentations selected for the plenary session at ASCO 2016.
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology - Emerging Therapies, Online First
Serial vaccination with galinpepimut-S induces immunologic responses in patients with acute myeloid leukemia (AML) who are in remission. Disease-free survival (DFS) and overall survival (OS) improved in patients with AML who had an immune response to galinpepimut-S, according to data from a phase 2 trial of galinpepimut-S that were presented at ASCO 2016.
A new biosimilar to trastuzumab (Herceptin) antibody, MYL-14010, showed efficacy and safety comparable to the reference drug (trastuzumab) as first-line treatment for patients with HER2-positive advanced breast cancer, according to results from the 24-week, randomized phase 3 HERITAGE study presented at ASCO 2016.
New data from an interim analysis of the head-to-head, open-label, phase 3, Japanese study J-ALEX show that alectinib (Alecensa) significantly improved progression-free survival (PFS) compared with crizotinib (Xalkori) in the frontline setting, said Hiroshi Nokihara, MD, PhD, of the National Cancer Center Hospital, Tokyo, Japan.
The combination of the checkpoint inhibitor nivolumab with the anti-CTLA (cytotoxic T-lymphocyte antigen)-4 ipilimumab results in durable responses in patients with advanced small-cell lung cancer (SCLC) or advanced non–small-cell lung cancer (NSCLC), according to the results of 2 separate clinical studies presented at ASCO 2016.
Ongoing clinical trials at academic centers around the country are testing a new strategy of matching available targeted therapies to molecular abnormalities in tumors instead of treating the cancer site.
Page 2 of 4
Results 11 - 20 of 33
Results 11 - 20 of 33